<p align="center">

  <!-- FULL BADGE COLLECTION -->
  <img src="https://img.shields.io/badge/Field-Clinical%20Data%20Science-blue?style=for-the-badge">
  <img src="https://img.shields.io/badge/Domain-Survival%20Analysis-orange?style=for-the-badge">
  <img src="https://img.shields.io/badge/Method-Kaplan--Meier%20%7C%20Cox%20PH-green?style=for-the-badge">
  <img src="https://img.shields.io/badge/Data-Clinical%20Trial%20(VAP%20Study)-purple?style=for-the-badge">
  <img src="https://img.shields.io/badge/Source-Randomized%20Controlled%20Trial-red?style=for-the-badge">
  <img src="https://img.shields.io/badge/Python-3.10+-yellow?style=for-the-badge&logo=python">
  <img src="https://img.shields.io/badge/Notebook-Jupyter-orange?style=for-the-badge&logo=jupyter">
  <img src="https://img.shields.io/badge/Libraries-lifelines%2C%20pandas%2C%20matplotlib-brightgreen?style=for-the-badge">
  <img src="https://img.shields.io/badge/Status-Completed-success?style=for-the-badge">

</p>

<hr>

# **Survival Analysis of Chlorhexidine Trial Outcomes Using Python** ğŸ§ªğŸ“ˆ

This project is based on a real clinical trial titled  
**â€œEffectiveness of Oral Hygiene with Chlorhexidine Mouthwash with 0.12 percent and 0.2 percent Concentration on Incidence of VAPâ€**  
published in *Annals of International Medical and Dental Research (2021)*.  
The complete article is included as  
**/data/Effectiveness of Oral Hygiene with Chlorhexidine Mouthwash.pdf**.

This repository analyses **time-to-VAP (Ventilator-Associated Pneumonia)** using classical Survival Analysis methods in Python. All results, tables, and plots are generated via **Chlorhexidine_Trials.ipynb**.

---

## **1ï¸âƒ£ Project Title**  
**Survival Analysis of Chlorhexidine Trial Outcomes Using Python**

---

## **2ï¸âƒ£ Project Summary** âœï¸

This project evaluates **0.12% vs 0.20% chlorhexidine** in preventing VAP in ventilated ICU patients.

- **Outcome:** Days until VAP (event = 1) or censoring (0).  
- **Need for survival analysis:** Follow-up varies and censoring is high.  
- **Methods used:** Kaplanâ€“Meier curves, Log-Rank test, Cox PH model, Schoenfeld residual checks.

---

## **3ï¸âƒ£ Dataset Description** ğŸ“š

- **Source:** Randomized controlled trial (140 patients).  
- **Working dataset:** Cleaned file `Raw Data from Chlorhexidine Trial.xlsx`.

### **Core Variables**
| Column | Description | Type |
| ------ | ----------- | ---- |
| Age | Years | Continuous |
| Gender | Male / Female | Categorical |
| TrialArm_num | 1 = 0.12%, 2 = 0.20% | Categorical |
| APACHEII | Severity score | Continuous |
| TLC_D1 | Day-1 total leukocyte count | Continuous |
| time | Time to VAP / censor | Continuous |
| event | 1 = VAP, 0 = NO VAP | Binary |

---

## **4ï¸âƒ£ Problem Statement** â“

1. Does 0.20% chlorhexidine reduce hazard of VAP compared to 0.12%?  
2. Are VAP-free survival curves significantly different between arms?  
3. Do Age, APACHE II, TLC Day 1, or Gender influence time-to-VAP?  
4. What does the Log-Rank test show?  
5. What do Cox PH hazard ratios indicate clinically?

---

## **5ï¸âƒ£ Objectives** ğŸ¯

1. Clean and preprocess data  
2. Perform EDA and baseline summaries  
3. Estimate KM curves (overall and by arm)  
4. Conduct Log-Rank comparison  
5. Fit Cox PH model  
6. Test PH assumptions  
7. Generate clear visualizations and interpretations  

---

## **6ï¸âƒ£ Methodology** ğŸ› ï¸

### **6.1 Data Preparation**

- Cleaned column names for compatibility.  
- Encoded TrialArm and Gender numerically.  
- Ensured `time` and `event` are numeric.  
- **Model variables:** `time`, `event`, `Age`, `APACHEII`, `TLC_D1`, `TrialArm_num`, `Gender_binary`.

**Handling Missing Values**  
- Median imputation for APACHEII and TLC_D1 (robust to skewed clinical values).

---

### **6.2 Exploratory Data Analysis (EDA)** ğŸ”

**Baseline Summary**
- N = 106, Events = 10  
- Mean Age â‰ˆ 47.6  
- Mean APACHEII â‰ˆ 16.9  
- Mean TLC Day1 â‰ˆ 15,216  
- Arm1 = 61, Arm2 = 45  
- Male = 93, Female = 13  
- Average follow-up â‰ˆ 5.7 days  

**Visual Exploration**
- **Age Histogram:** Wide adult distribution.  
- **APACHE II Histogram:** Most between 10â€“20.  
- **TLC Day1 Boxplot:** Elevated counts typical for ICU.

**Life Tables**
- Early time points show almost no events.  
- Most VAP events occur between days 5â€“10.

**Event / Censoring**
- Heavy censoring due to discharge, LAMA, or death.

**Survival Visual Checks**
- KM curves (overall + by arm) confirm readiness for modelling.

---

### **6.3 Survival Modelling**
- KM curves (overall and stratified)  
- Log-Rank test  
- Cox PH multivariable model  
- PH assumption testing (Schoenfeld residuals)

---

## **7ï¸âƒ£ Python Implementation Structure** ğŸ’»

.
â”œâ”€â”€ data/
â”‚ â”œâ”€â”€ Chlorhexidine Trials.xlsx
â”‚ â”œâ”€â”€ Data_Dictionary.png
â”‚ â”œâ”€â”€ Effectiveness of Oral Hygiene with Chlorhexidine Mouthwash.pdf
â”‚ â”œâ”€â”€ Raw Data from Chlorhexidine Trial.xlsx
â”‚
â”œâ”€â”€ results/
â”‚ â”œâ”€â”€ cox_ph.png
â”‚ â”œâ”€â”€ cox_summary.png
â”‚ â”œâ”€â”€ km_by_arm.png
â”‚ â”œâ”€â”€ km_overall.png
â”‚ â”œâ”€â”€ ph_TLCD1.png
â”‚ â”œâ”€â”€ ph_Trial_arm.png
â”‚ â”œâ”€â”€ ph_age.png
â”‚ â”œâ”€â”€ ph_apache2.png
â”‚ â”œâ”€â”€ ph_gender.png
â”‚
â”œâ”€â”€ Chlorhexidine_Trials.ipynb
â”œâ”€â”€ LICENSE
â”œâ”€â”€ README.md

---


---

## **8ï¸âƒ£ Key Visualizations** ğŸ“Š

- KM curves (overall and by arm)  
- Life tables  
- Schoenfeld residual plots  
- Cox model summary  
- Forest-style HR table  

---

## **9ï¸âƒ£ Results & Interpretation** ğŸ§¾

### **1. Kaplanâ€“Meier Survival (Overall)**  
<div align="center">
  <img src="results/km_overall.png" width="600">
</div>

VAP-free survival remains above 90% during the observation window, reflecting low event count and early censoring.

---

### **2. Kaplanâ€“Meier by Trial Arm**  
<div align="center">
  <img src="results/km_by_arm.png" width="600">
</div>

- Arm 1: more drops in survival  
- Arm 2: fewer events  
- Visual trend favors 0.20%, but statistical testing required.

---

### **3. Log-Rank Test**  
- **p = 0.94** â†’ No statistically significant difference in survival curves.

---

### **4. Cox Proportional Hazards Model**  
<div align="center">
  <img src="results/cox_summary.png" width="600">
</div>

- TrialArm HR = **0.97**, p = **0.97** â†’ No measurable hazard difference  
- Other predictors also insignificant (HR â‰ˆ 1.0)  
- Concordance â‰ˆ 0.59  

---

### **5. PH Assumption**  
<div align="center">
  <img src="results/cox_ph.png" width="600">
</div>

- All covariates satisfy PH assumption (p > 0.05).

---

### **Summary Table (Selected)**  
- Survival @ Day 5: Arm1 â‰ˆ 0.919 | Arm2 â‰ˆ 0.902  
- Events (filtered dataset): Arm1 = 6 | Arm2 = 4  
- TrialArm HR â‰ˆ 0.97  

---

## **ğŸ”Ÿ Discussion** ğŸ’¬

Both chlorhexidine concentrations maintained high VAP-free survival. Although the 0.20% arm showed fewer events, the survival curves and hazard timelines were similar, which is reflected by the non-significant log-rank and Cox results.

The Cox model yielded HRs close to one for all predictors, and PH checks confirmed time-independent effects. These findings align with clinical expectationsâ€”chlorhexidine supports oral hygiene, and both concentrations performed similarly in this dataset.

Survival analysis added structure by evaluating timing, hazards, and group comparisons beyond simple event counts.

---

## **1ï¸âƒ£1ï¸âƒ£ Conclusion** âœ…

- Both chlorhexidine strengths show high VAP-free survival.  
- No statistically significant difference between 0.12% and 0.20% in time-to-VAP.  
- No strong predictors of VAP identified.  
- Survival modelling effectively supports clinical interpretation.

---

## **1ï¸âƒ£2ï¸âƒ£ Future Work** ğŸ”­

- Include time-varying covariates  
- Fit parametric survival models  
- Apply machine-learning survival methods  
- Validate on external ICU datasets  
- Explore competing-risk analysis  

---

### Contact / Citation  
- Original study: *Nagesh Vyas, Priya Mathur, Shailesh Jhawar, Akash Prabhune, Pradeep Vimal (2021).*  
- Notebook: `Chlorhexidine_Trials.ipynb`  
- PDF: `/data/Effectiveness of Oral Hygiene with Chlorhexidine Mouthwash.pdf`

---

**End of README**
